Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CollaGenex Periostat NDA filed for oral doxycycline to treat periodontitis.

Executive Summary

COLLAGENEX PERIOSTAT ORAL DOXYCYCLINE DENTAL NDA FILED for treatment of periodontitis on Aug. 30, the Newtown, Penn. dental therapies R&D firm announced Sept. 4. The NDA includes data on three Phase III trials of 436 patients; the 12-month dosing trials found that Periostat demonstrated both clinically and statistically significant improvements in tooth attachment levels, gum pocket depth and bleeding upon probing. The daily dosage is 20 mg doxycycline.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028811

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel